Abstract: A method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2).
Type:
Grant
Filed:
June 5, 2012
Date of Patent:
November 10, 2015
Assignee:
NOVARTIS FORSCHUNGSSTIFTUNG ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
Inventors:
Mohamed Bentires-Alj, Nicola Aceto, Michael Stadler
Abstract: The present invention relates to a method of inhibiting metastasis comprising the administration of an inhibitor of protease nexin-1 (PN-1), characterized in that said inhibitor is administered at a therapeutical dosage that does not completely inhibit the expression and/or activity of PN-1.
Type:
Grant
Filed:
December 5, 2008
Date of Patent:
January 13, 2015
Assignee:
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Abstract: The present invention relates to a method for treating cancer, for instance brain tumors, in a subject by inhibiting a teneurin by administering to said subject a therapeutically effective amount of a modulator of said teneurin, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of teneurin.
Type:
Grant
Filed:
November 6, 2009
Date of Patent:
February 4, 2014
Assignee:
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Inventors:
Ruth Chiquet-Ehrismann, Daniela Kenzelmann Bro{hacek over (z)}
Abstract: The present invention provides a genetically-modified non-human animal whose somatic and germ cells contain an exogenous gene encoding a recombinant fusion protein, wherein the presence, and expression, of said recombinant fusion protein renders said genetically-modified non-human animal sterile. Tools for generating such sterile genetically-modified non-human animal as well as methods of use thereof are also provided.
Type:
Grant
Filed:
August 26, 2010
Date of Patent:
January 21, 2014
Assignees:
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute for Biomedical Research, Universität Zürich
Inventors:
Pawel Pelczar, Thorsten Buch, Antoine Peters
Abstract: The invention provides a new reproducible transgenic mouse model for the study of iron accumulation in the body. In particular, the invention concerns the study of iron overload in an RGMc knockout mouse model and its use in drug discovery and research.
Type:
Grant
Filed:
July 22, 2005
Date of Patent:
January 24, 2012
Assignee:
Novartis Forschungsstiftung, Zweigniederalassung Friedrich Miescher Institute for Biomedical Research
Abstract: The FNIII13 domain of fibronectin and smaller fragments thereof have a tumour cell proliferation inhibitory effect. Compositions are provided comprising fragments of fibronectin having the FNIII 13 domain and fragments thereof. A system comprising cells exposed to fibronectin and caused to proliferate by the presence of tenascin are used as an in vitro method for screening possible anti-tumour agents. Cell-free systems comprising a fibronectin ligand and tenascin are also employed for screening potential anti-tumour or anti-cancer agents. Test compounds are assayed for the ability to disrupt binding of the fibronectin ligand to tenascin. A further cell-free system additionally includes a syndecan molecule.
Type:
Grant
Filed:
September 18, 2006
Date of Patent:
September 13, 2011
Assignee:
Novartis Forschungesstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Abstract: The present invention relates to the phosphorylated form of nuclear serine/threonine protein kinase, designated nuclear, Dbf2-related kinase (Ndr), and provides assays and materials for identifying modulators thereof. The invention relates to the fields of molecular biology, chemistry, pharmacology, and screening technology.
Type:
Grant
Filed:
November 25, 2003
Date of Patent:
August 30, 2011
Assignee:
Novartis Forschungesstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Inventors:
Samuel Joseph Bichsel, Brian Arthur Hemmings, Mario Reinhard Stegert, Rastislav Tamaskovic
Abstract: This invention provides purified PKB Ser 473 kinase and methods of purifying it. The methods involve the use of several sequential steps, including subcellular fractionation to isolate a plasma membrane fraction and the use of gel filtration or chromatography that separates molecules according to their size or affinity.
Type:
Grant
Filed:
June 12, 2003
Date of Patent:
September 14, 2010
Assignee:
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Inventors:
Jianhua Feng, Brian A Hemmings, Michelle M Hill
Abstract: Tenascin-W, an extracellular matrix molecule that is specifically expressed in metastatic tumours is provided. A system comprising a sample expressing tenascin-W is used as an in vitro method for screening possible anti-tumour agents or for agents that promote osteogenesis.
Type:
Grant
Filed:
March 26, 2003
Date of Patent:
March 23, 2010
Assignee:
Novartis Forschungsstiftung Zweignlederlassung Friedrich Miescher Institute for Biomedical Research
Abstract: A human protein (designated Carboxy-terminal Modulating protein, CTMP) is described and is identified as having tumour suppressor properties. CTMP has been shown to interact with protein kinase B and inhibit protein kinase B activity, establishing its importance in the protein kinase B signalling pathway.
Type:
Grant
Filed:
June 7, 2001
Date of Patent:
July 8, 2008
Assignee:
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Abstract: There is provided a method of identifying a PAR cleaving molecule comprising the steps of: (a) providing an immobilized PAR cleavage peptide linked to a reporter molecule; (b) contacting the immobilized PAR cleavage peptide with a PAR cleaving molecule; and (c) detecting release of the reporter molecule.
Type:
Grant
Filed:
December 13, 2000
Date of Patent:
December 12, 2006
Assignee:
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research